"At a cost of $7K/year, this translates to $958K per event saved. Thus, in our view, payers will continue to restrict access to the drug," Bernstein analyst Ronny Gal wrote in a note. He said the study shows that the drug prevents only one cardiovascular event per 137 treated patients.
Amgen said that medication's results do justify the price tag. Not only does the study confirm that Repatha — also known as Evolocumab — serves its intended function, but the study revealed no new side effects.
"This is a game changer for high-risk patients," Sean E. Harper, M.D., executive vice president of research and development at Amgen, said in a release.
"Even though these patients were optimally treated with the latest therapies, they were still at high risk for an additional cardiac event," he said. "It's remarkable to see such a large impact in reducing cardiac events given that this patient population was only on Repatha for about two years."